David Grainger
British life-sciences investor and drug developer, venture partner at Medicxi and chief executive of Methuselah Health.
Ficha técnica
No existe un retrato disponible bajo licencia libre
- Cargo actual
- Venture Partner, Medicxi; Chief Executive, Methuselah Health
- Organización
- Medicxi
- País
- United Kingdom
Este artículo aún no está disponible en este idioma. A continuación se muestra la versión en inglés.
David Grainger (born 12 October 1966) is a British life-sciences investor and drug developer. He is a co-founder and venture partner of Medicxi, a European venture capital firm focused on life sciences, having previously worked in the life-sciences practice of Index Ventures.
He is chief executive of Methuselah Health, a United Kingdom company applying proteomics to the development of treatments for age-related disease, and was formerly Chief Innovation Officer of Centessa Pharmaceuticals.
Grainger has co-founded and chaired several biotechnology companies, among them XO1, later acquired by Janssen Pharmaceuticals, and Morphogen-IX, and led investments including Padlock Therapeutics, acquired by Bristol-Myers Squibb. He has also written on the pharmaceutical industry for Forbes.
Formación académica
- University of Cambridge